Literature DB >> 6443014

A rapid method for testing in vivo the susceptibility of different strains of Trypanosoma cruzi to active chemotherapeutic agents.

L S Filardi, Z Brener.   

Abstract

A method is described which permits to determine in vivo and in a short period of time (4-6 hours) the sensitivity of T. cruzi strains to known active chemotherapeutic agents. By using resistant- and sensitive T. cruzi strains a fairly good correlation was observed between the results obtained with this rapid method (which detects activity against the circulating blood forms) and those obtained with long-term schedules which involve drug administration for at least 20 consecutive days and a prolonged period of assessment. This method may be used to characterize susceptibility to active drugs used clinically, provide information on the specific action against circulating trypomastigotes and screen active compounds.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6443014     DOI: 10.1590/s0074-02761984000200008

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  10 in total

1.  Sesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental Chagas disease.

Authors:  Renata Tupinambá Branquinho; Vanessa Carla Furtado Mosqueira; Jaquelline Carla Valamiel de Oliveira-Silva; Marianne Rocha Simões-Silva; Dênia Antunes Saúde-Guimarães; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

2.  Differential gene expression in benznidazole-resistant Trypanosoma cruzi parasites.

Authors:  Diana Villarreal; Philippe Nirdé; Mallorie Hide; Christian Barnabé; Michel Tibayrenc
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.

Authors:  Carlos Wong-Baeza; Benjamín Nogueda-Torres; Manuel Serna; Sergio Meza-Toledo; Isabel Baeza; Carlos Wong
Journal:  BMC Pharmacol Toxicol       Date:  2015-04-22       Impact factor: 2.483

4.  Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies.

Authors:  Isidro Palos; Edgar E Lara-Ramirez; Julio Cesar Lopez-Cedillo; Carlos Garcia-Perez; Muhammad Kashif; Virgilio Bocanegra-Garcia; Benjamin Nogueda-Torres; Gildardo Rivera
Journal:  Molecules       Date:  2017-06-18       Impact factor: 4.411

5.  Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning.

Authors:  Melissa F Adasme; Sarah Naomi Bolz; Lauren Adelmann; Sebastian Salentin; V Joachim Haupt; Adriana Moreno-Rodríguez; Benjamín Nogueda-Torres; Verónica Castillo-Campos; Lilián Yepez-Mulia; José A De Fuentes-Vicente; Gildardo Rivera; Michael Schroeder
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

6.  Participation of Central Muscarinic Receptors on the Nervous Form of Chagas Disease in Mice Infected via Intracerebroventricular with Colombian Trypanosoma cruzi Strain.

Authors:  Gabriela Maira Pereira de Assis; Micheline Freire Donato; Matheus Marques Milagre; Samantha Ribeiro Béla; Mayra Fernanda Ricci; Luara Augusta Batista; Maria Elena de Lima; Fabrício de Araujo Moreira; Rosa Maria Esteves Arantes; Marta de Lana
Journal:  Pathogens       Date:  2021-01-25

7.  One-Pot Multicomponent Synthesis of Methoxybenzo[h]quinoline-3-carbonitrile Derivatives; Anti-Chagas, X-ray, and In Silico ADME/Tox Profiling Studies.

Authors:  Hegira Ramírez; Katiuska Charris; Esteban Fernandez-Moreira; Benjamín Nogueda-Torres; Mario V Capparelli; Jorge Ángel; Jaime Charris
Journal:  Molecules       Date:  2021-11-19       Impact factor: 4.411

8.  Biological features of TcM: A new Trypanosoma cruzi isolate from Argentina classified into TcV lineage.

Authors:  Santiago José Martinez; Gonzalo Nicolás Nardella; Matías Exequiel Rodríguez; Cynthia Vanesa Rivero; Fernán Agüero; Patricia Silvia Romano
Journal:  Curr Res Microb Sci       Date:  2022-06-30

Review 9.  Quality of Reporting and Adherence to ARRIVE Guidelines in Animal Studies for Chagas Disease Preclinical Drug Research: A Systematic Review.

Authors:  Julián Ernesto Nicolás Gulin; Daniela Marisa Rocco; Facundo García-Bournissen
Journal:  PLoS Negl Trop Dis       Date:  2015-11-20

Review 10.  Precision Health for Chagas Disease: Integrating Parasite and Host Factors to Predict Outcome of Infection and Response to Therapy.

Authors:  Santiago J Martinez; Patricia S Romano; David M Engman
Journal:  Front Cell Infect Microbiol       Date:  2020-05-08       Impact factor: 6.073

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.